Business
Dr Roch Doliveux appointed Non-Executive Chairman
Dr Roch Doliveux appointed Non-Executive Chairman.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n RNS Number : 4556O\n Oxford Biomedica PLC\n 01 June 2020\n \n \n \n \n Oxford Biomedica Appoints Dr. Roch Doliveux as Non-Executive Chairman \n \n \n \n \n \n \n Oxford, UK - 1 June, 2020: \n \n Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Group\"), a leading gene and cell therapy group, is pleased to announce that Dr. Roch Doliveux will become Non-Executive Chairman of the Group with effect from 24 June 2020. As announced on 18 March 2020, Dr Lorenzo Tallarigo informed the Group of his intention to retire from Oxford Biomedica's Board. Dr Tallarigo will step down as Chairman at the Group's AGM on 23 June 2020. Accordingly, Dr Tallarigo will no longer be standing for reappointment at the AGM and the resolution regarding his reappointment will be withdrawn.\n \n \n \n \n \n Dr. Doliveux is currently the Chairman of the Board of Directors at Pierre Fabre S.A and a Non-Executive Director at Stryker Corporation and UCB SA. Dr. Doliveux was previously the Chief Executive Officer of UCB SA for ten years during which time he transformed the company from a diversified chemical group into a global biopharmaceutical leader. Prior to that he worked at Schering-Plough International, Inc from 1990-2003 and at Ciba-Geigy AG (now Novartis) from 1982. \n \n \n \n \n \n Dr. Doliveux is also Chairman of the GLG Healthcare Institute, a community of senior executives for experience sharing and learning. He was Vice-President of the European Federation of Pharmaceutical Association (EFPIA) Board and Chairman of the Board of the Innovative Medicines Initiative (IMI) which is the largest healthcare public private partnership in the world. Dr. Doliveux also chairs the Caring Entrepreneurship Fund (King Baudouin Foundation), a philanthropic initiative which he created in 2008 which supports entrepreneurship in health and wellness. Dr. Roch Doliveux is a Veterinary Surgeon by training and has an MBA from INSEAD.\n \n \n \n \n \n There are no further disclosures required to be made in accordance with LR 9.6.13R.\n \n \n \n \n \n \n John Dawson, Chief Executive Officer of Oxford Biomedica, said:\n \n \n \n \"Roch has extensive global experience with life science and healthcare companies including in leadership, strategy, financials, Board governance and has a passi...